TB-500 in GLOW provides the actin-related and systemic tissue repair component of the three-peptide research formulation. As a synthetic peptide related to thymosin beta-4, TB-500 brings the research base of one of the most abundant intracellular proteins to the GLOW combination. As the TB-500 component of the GLOW research cluster, this article reviews the published literature on TB-500 with focus on its role in the GLOW formulation.
TB-500 in GLOW: Thymosin Beta-4 Research Literature
GLOW Blend · Published April 9, 2026 · Updated May 18, 2026 · 8 min read
Quick Answer
TB-500 in the GLOW blend contributes actin-sequestering activity, cell migration support, and angiogenic signaling alongside GHK-Cu and BPC-157. This article covers the thymosin beta-4 research context and the TB-500 role in three-peptide skin and tissue repair formulations. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Frequently Asked Questions
What is TB-500 in research contexts?
+
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide. The fragment contains the LKKTETQ actin-binding motif and is studied in preclinical models for its effects on cell migration, angiogenesis, and tissue repair.
What role does TB-500 play in the GLOW blend?
+
TB-500 contributes actin-sequestering activity that supports cell migration and angiogenesis, complementing BPC-157's localized cytoprotection and GHK-Cu's collagen synthesis effects in the multi-peptide skin and connective tissue research blend.
What thymosin beta-4 research informs TB-500's role in GLOW?
+
Foundational thymosin beta-4 research demonstrates roles in wound healing, vascular development, and tissue regeneration. TB-500, as the active fragment containing the LKKTETQ motif, brings these mechanisms into the multi-peptide research context of GLOW.
Is TB-500 approved for human use?
+
No. TB-500 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Glossary
Key terms used in this article.
- Thymosin Beta-4
- The endogenous 43-amino-acid parent peptide from which TB-500 is derived.
- Actin Sequestration
- The binding of monomeric G-actin to prevent polymerization, regulating cytoskeletal dynamics.
- LKKTETQ Motif
- The seven-amino-acid actin-binding sequence within thymosin beta-4 responsible for sequestering G-actin.
- Cell Migration
- The directed movement of cells in response to chemical or mechanical cues, critical to repair and angiogenesis.
- Multi-Peptide Blend
- A research formulation combining two or more peptides to study additive or synergistic biological effects.
- Dermal Repair
- The biological processes that restore skin structure and function after injury, including re-epithelialization and matrix remodeling.
- Synergy
- A pharmacological effect in which two or more agents produce a combined effect greater than the sum of their individual effects.
- Photoaging
- Skin damage and accelerated aging caused by chronic ultraviolet radiation exposure, distinct from intrinsic chronological aging.
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
